StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics cash

Cash and short-term investments held at the end of each period.

Xilio Therapeutics's cash was $136.04M at Jun 30, 2026. For fiscal 2025 it was $137.53M, up 141.0% from the year before. The highest annual figure on record is $199.61M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$137.53M+141.0%
FY2024Dec 31, 2024$57.07M+23.3%
FY2023Dec 31, 2023$46.29M-62.0%
FY2022Dec 31, 2022$121.95M-38.9%
FY2021Dec 31, 2021$199.61M+860.2%
FY2020Dec 31, 2020$20.79M-57.6%
FY2019Dec 31, 2019$49.04M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$136.04M+11.9%
Q1 FY2026Mar 31, 2026$150.33M+68.8%
Q4 FY2025Dec 31, 2025$137.53M+141.0%
Q3 FY2025Sep 30, 2025$103.76M+69.4%
Q2 FY2025Jun 30, 2025$121.55M+62.2%
Q1 FY2025Mar 31, 2025$89.07M+162.1%
Q4 FY2024Dec 31, 2024$57.07M+23.3%
Q3 FY2024Sep 30, 2024$61.26M+2.5%
Q2 FY2024Jun 30, 2024$74.95M-0.6%
Q1 FY2024Mar 31, 2024$33.98M-63.6%
Q4 FY2023Dec 31, 2023$46.29M-62.0%
Q3 FY2023Sep 30, 2023$59.77M-57.0%
Q2 FY2023Jun 30, 2023$75.38M-52.7%
Q1 FY2023Mar 31, 2023$93.27M-47.3%
Q4 FY2022Dec 31, 2022$121.95M-38.9%
Q3 FY2022Sep 30, 2022$139.14M+39.5%
Q2 FY2022Jun 30, 2022$159.41M+32.5%
Q1 FY2022Mar 31, 2022$176.96M+25.3%
Q4 FY2021Dec 31, 2021$199.61M+860.2%
Q3 FY2021Sep 30, 2021$99.77M+198.0%
Q2 FY2021Jun 30, 2021$120.30M+145.3%
Q1 FY2021Mar 31, 2021$141.22M–
Q4 FY2020Dec 31, 2020$20.79M–
Q3 FY2020Sep 30, 2020$33.48M–
Q4 FY2019Dec 31, 2019$49.04M–

More Xilio Therapeutics figures

See a number that looks wrong?